

Balding and Prostate Cancer: Lilac Corp reviews a study and recommends Nolopecia, a natural treatment against hair loss

Lilac Corp reviews a study that tested a possible link between early hair loss and prostate cancer.

SARASOTA, FL, UNITED STATES, June 6, 2018 /EINPresswire.com/ -- A study showed that men with very early onset balding are more likely to develop aggressive prostate cancer, and at a younger age [1]. Some prostate cancers are more dangerous than others. Prostate cancer and androgenic alopecia, also called male pattern baldness, are both dependent on androgen hormones.

The study surveyed 1,941 men and found that men balding at age 20 years had a 50% higher chance of developing aggressive prostate cancer. Also, these men were diagnosed with cancer an average of 16 months earlier than non-balding men. Men balding at age 40 years and older, or non-balding men did not have the increased risk. Research



like this is important because it helps to identify groups of men with higher risk for aggressive cancer. Men who are at a higher risk can perform regular screening tests for prostate cancer and should be followed up closely with their doctor.



Nolopecia, targets the latent viruses in the body. This helps the body maintain a normal level of the 5alpha-R, DHT, and AR proteins. A normal level of these proteins stimulates hair growth."

Lilac Corp

For men (and women), who suffer from <a href="https://nair.loss.com/hair


The new treatment, called Nolopecia, targets the latent viruses in the body. This helps the body maintain a normal level of the 5alpha-R, DHT, and AR proteins. A normal level

of these proteins stimulates hair growth.

There are many treatments for hair loss on the market. However, only Nolopecia targets the latent viruses that cause the increase in 5alpha-R, DHT, and AR observed in people with hair loss and balding.

About Lilac Corp:

Lilac Corp specializes in the development of biology-based patent protected natural treatments. Currently, Lilac Corp is selling four products: Gene-Eden-VIR, Novirin, Nolopecia, and Noacnin. Lilac Corp ships its products to more than 100 countries around the world. What makes Lilac Corp special is



that all its products are tested in clinical studies that follow FDA guidelines. To ensure transparency, the results of the clinical studies are published in leading scientific journals. Lilac Corp also offers a 90-day money back guarantee.

Source:

[1] Papa, N., MacInnis, R., English, D., Bolton, D., Davis, I., & Lawrentschuk, N. et al. (2017). Early-onset baldness and the risk of aggressive prostate cancer: findings from a case—control study. Cancer Causes & Control, 29(1), 93-102. doi: 10.1007/s10552-017-0981-0

John Evans Lilac Corp 585-250-9999 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.